Log In
Print
BCIQ
Print
Print this Print this
 

rhNAGLU (SBC-103)

  Manage Alerts
Collapse Summary General Information
Company Synageva BioPharma Corp.
DescriptionRecombinant human N-acetylglucosaminidase alpha (NAGLU)
Molecular Target N-acetylglucosaminidase alpha (NAGLU)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome)
Regulatory Designation

U.S. - Orphan Drug (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today